VISTAGEN THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements of 282.85 thousand shares for the 12-month period ending 2015-03-31, per its 10-K filed 2015-06-29.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements · last filed 2015-06-29
- VISTAGEN THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2015 was 282.85K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 12 month |
|---|---|
| 2015-03-31 | 282.85K shares 10-K · filed 2015-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |